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Abstract 
 
UDP-glucuronosyltransferases (UGTs) catalyze the glucuronidation of a variety of 
xeno/endobiotics. UGTs are type I membrane proteins of the endoplasmic reticulum (ER) 
with a glycosylated luminal domain. In the present study, we investigated the role of 
N-glycosylation in the function of human UGT1A9. Mutation analysis at the potential 
N-glycosylation sites at residues 71, 292, and 344 (from asparagine to glutamine) revealed 
that all of them were glycosylated, but the extent of glycosylation and/or size of the glycan 
differed. In comparison with the wild type, these mutants showed decreased enzyme activities 
in parallel with the extent of the band shift in Western blot analysis. To evaluate the role of 
glycosylation in the enzyme activity, we produced unglycosylated UGT1A9 by treating 
HEK293 cells transiently transfected with expression plasmid with tunicamycin. The 
unglycosylated UGT1A9 was almost inactive, which was not an indirect effect of ER stress. 
To the contrary, the deglycosylated UGT1A9, which was produced by the treatment with 
Endo H under the non-denaturing condition, showed the same enzyme kinetics as the control. 
These results suggest that the glycosylation that occurs during translation is important for the 
folding of UGT1A9. The thermal stability analysis of the mutated and deglycosylated 
UGT1A9 proteins supported the findings. In conclusion, we found that the N-glycosylation 
has an important role in the folding of UGT1A9.  
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1. Introduction 
 
Over half of all proteins in nature are glycosylated, and more than three quarters of them 
contain N-linked glycan [1]. N-Linked glycosylation occurs at the asparagine (N) residue of 
the NX(S/T) consensus sequence of a protein, where X is any amino acid except proline. It is 
estimated that approximately 70-90% of the consensus sequences are glycosylated [2]. 
N-Glycosylation is one of the most common and yet complex forms of post-translational 
modification. It is intricately involved in various cellular processes including protein folding, 
protein secretion, intracellular trafficking, stability, binding affinity, enzyme activity, and 
substrate specificity, enabling fine-tuning of a protein’s function [3]. 
UDP-Glucuronosyltransferases (UGTs) are a superfamily of enzymes that catalyze the 
glucuronidation of numerous xenobiotic and endobiotic compounds [4]. The reaction results 
in the formation of hydrophilic glucuronides that are easily excreted into bile or urine. Thus, 
UGTs are centrally involved in the metabolism and detoxification of drugs, pollutants and 
toxic substances. Currently, 19 human UGTs have been identified and are classified into two 
families, UGT1 and UGT2. UGTs are type I endoplasmic reticulum (ER) resident membrane 
proteins with a single transmembrane domain near the carboxyl-terminus, and most parts 
including the catalytic domain are located on the luminal side [5,6]. Earlier studies have 
reported that several UGT isoforms such as human UGT1A6 [7], UGT2B7, UGT2B15, 
UGT2B17, monkey UGT2B20 [8], rat UGT2B1, and UGT2B2 [9] are N-glycosylated. 
Accumulating evidence suggests that some proteins are dependent on the glycosylation for 
biological activity, whereas the function of others is not altered by this post-translational 
modification. As for UGTs, it has been demonstrated that deglycosylation of the purified 
rabbit UGT1A6, UGT2B13, rat UGT1A6 and UGT2B2 proteins by endoglycosidase H (Endo 
H) did not decrease their enzyme activities [10]. Mackenzie [9] has reported that rat UGT2B1 
and UGT2B2 are N-glycosylated and the treatment of COS cells expressing these UGTs with 
tunicamycin, which inhibits the first step of N-glycosylation, i.e., translocation of 
oligosaccharide core units to peptides, resulted in the production of less active enzymes. 
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However, the unglycosylated proteins showed similar substrate specificity and protein 
stability as the native proteins. Barbier et al. [8] have reported that human UGT2B15 and 
monkey UGT2B20, in which the glycosylation was abolished by the mutation of asparagine 
residues, showed decreased velocity of glucuronidation, but no changes in the Km values and 
substrate specificities. Additionally, it has been demonstrated that some other UGT isoforms 
including human UGT2B4, monkey UGT2B23, and rat UGT2B3 are not glycosylated [8,11]. 
Thus, the physiological and biological significance of the N-glycosylation of UGT proteins 
remains to be clarified. In this study, we evaluated the role of N-glycosylation of human 
UGT1A, focusing UGT1A9 because it catalyzes the glucuronidation of a variety of drugs, 
dietary constituents, steroids, and fatty acids [12-14] and there is no report for the 
glycosylation of this enzyme. We performed a series of studies using Endo H and 
tunicamycin as well as mutation analysis for recombinant UGT1A9 enzyme. Kinetic analysis, 
SDS-PAGE analysis under the non-reducing condition, and thermal stability analysis were 
conducted to elucidate the role of glycosylation of UGT1A9. 
 
2. Materials and Methods 
 
2.1. Materials 
     O-Glycosidase, tunicamycin, UDP-glucuronic acid (UDPGA), alamethicin 
4-methylumbelliferone (4-MU), and 4-MU O-glucuronide were purchased from 
Sigma-Aldrich (St. Louis, MO). Endoglycosidase H (Endo H) was from New England 
Biolabs (Ipswich, MA). Castanospermin, 1-deoxynojirimycin, thapsigargin, G-418 and 
propofol were purchased from Wako Pure Chemicals (Osaka, Japan). Rabbit anti-human 
UGT1A antibodies were obtained from BD Gentest (Woburn, MA). Rabbit anti-human 
GAPDH antibodies and mouse anti-KDEL antibodies were from Imgenex (San Diego, CA) 
and Stressgen (Ann Arbor, MI), respectively. IRDye680-labeled goat anti-rabbit secondary 
antibody and Odyssey Blocking Buffer were from Li-COR Biosciences (Lincoln, NE). 
Perfect NT Gel M was purchased from DRC (Tokyo, Japan). Taq DNA polymerase was 
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obtained from Greiner Japan (Tokyo, Japan). Primers were commercially synthesized at 
Hokkaido System Sciences (Sapporo, Japan). Restriction enzymes were purchased from 
Takara (Shiga, Japan), Toyobo (Osaka, Japan), Stratagene (La Jolla, CA), and New England 
Biolabs (Beverly, MA). Lipofectamine 2000 was purchased from Invitrogen (Carlsbad, CA). 
All other chemicals and solvents were of the highest or analytical grade commercially 
available. 
 
2.2. Treatment of recombinant UGT1As with Endo H or O-glycosidase 
     HEK293 cells stably expressing UGT1A1, UGT1A4, UGT1A6, or UGT1A9 were 
previously established in our laboratory [15]. The cells were grown in Dulbecco’s modified 
Eagle’s medium containing 4.5 g/l glucose, 10 mM HEPES, and 10% fetal bovine serum with 
5% CO2 at 37°C. Total cell homogenates were prepared by a method described previously 
[15]. Briefly, the cells were suspended in Tris-buffered saline [25 mM Tris-HCl buffer (pH 
7.4), 138 mM NaCl, and 2.7 mM KCl] and disrupted by freeze-thawing three times. The 
suspensions were homogenized with a Teflon-glass homogenizer for 10 strokes. The protein 
concentrations of the homogenates were determined according to Bradford [16]. Then, the 
homogenates were adjusted to a 2 mg/ml protein concentration with a denaturing buffer in a 
final concentration of 0.5% SDS and 40 mM DTT, and were denatured at 95°C for 10 min. 
The denatured proteins (10 µg) were incubated with 250 U of Endo H or 2.5 mU of 
O-glycosidase in 50 mM sodium citrate buffer (pH 5.5) in a final volume of 10 µl at 37°C for 
1 h, and were subjected to SDS-PAGE and immunoblotting. For the evaluation of enzyme 
activity, the recombinant UGT1A9 was treated with Endo H under the non-denaturing 
condition as follows: the total cell homogenates (10 µg) were incubated with 250 U Endo H 
in 200 mM Tris-HCl buffer (pH 7.5) in a final volume of 20 µl at 37°C for 1 h. 
 
2.3. SDS-PAGE and immunoblotting 
     The samples were boiled for 3 min in Laemmli sample buffer containing 
2-mercaptoethanol and separated on a 10% SDS-polyacrylamide gel. The separated proteins 
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were electrotransferred onto PVDF membrane Immobilon-P (Millipore, Billerica, MA). The 
membrane was washed with phosphate buffered saline (PBS) two times and blocked with 
Odyssey Blocking Buffer (Li-COR Biosciences, Lincoln, NE) for 1 h. The membranes were 
incubated with rabbit anti-human UGT1A polyclonal antibody (1:500), rabbit anti-human 
GAPDH antibodies (1:1000), or mouse anti-KDEL antibodies (1:200) diluted with Odyssey 
Blocking Buffer containing 0.1% Tween-20 for 1 h. The membrane was washed with PBST 
(PBS containing 0.1% Tween-20) four times and incubated with IRDye680-labeled goat 
anti-rabbit or anti-mouse IgG secondary antibody diluted (1:5000) with PBST for 1 h. The 
densities of the bands were determined using an Odyssey infrared imaging system (Li-COR 
Biosciences).  
 
2.4. Construction of expression plasmids of UGT1A9 mutants and transient transfection into 
HEK293 cells 
     Asparagine residues at the positions 71, 292, and 344 of UGT1A9 were mutated to 
glutamine using a QuickChange Site-Directed Mutagenesis Kit (Stratagene). The primer sets 
to construct the expression plasmids of single mutants N71Q, N292Q, and N344Q are shown 
in Table 1. The expression plasmids of double mutants N71Q/N292Q, N292Q/N344Q, and 
N71Q/N344Q and a triple mutant N71Q/N292Q/N344Q were constructed by digestion with 
appropriate restriction enzymes and ligation of the expression plasmids of single mutants. 
Nucleotide sequences were confirmed by DNA sequence analysis. HEK293 cells (1 x 106 
cells) seeded on 6-well plates were transfected with 4 µg of the expression plasmids using 
Lipofectamine 2000. After 48 h, the total cell homogenates were prepared as described above. 
 
2.5. 4-MU O-glucuronosyltransferase activity 
     4-MU O-glucuronosyltransferase activity was determined as described previously [15]. 
Briefly, a typical incubation mixture (200 µl of total volume) contained 50 mM Tris-HCl 
buffer (pH 7.4), 10 mM MgCl2, 2.5 mM UDPGA, 25 µg/ml alamethicin, 0.1 mg/ml cell 
homogenate, and 50 µM 4-MU. The reaction was initiated by the addition of UDPGA 
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following a 3-min preincubation at 37°C. After incubation at 37°C for 30 min, the reaction 
was terminated by the addition of 100 µl of ice-cold methanol. After removal of the protein 
by centrifugation at 13,000 g for 5 min, a 50-µl portion of the sample was subjected to HPLC. 
The analytical column was a CAPCEL PAK C18 UG120 (4.6 x 150 mm, 5 µm; Shiseido, 
Tokyo, Japan), and the mobile phase was 30% methanol/20 mM potassium phosphate buffer 
(pH 4.5). The eluent was monitored at 320 nm. The quantification of 4-MU O-glucuronide 
was performed by comparing the HPLC peak height to that of the authentic standard. 
     In kinetic analyses, the 4-MU concentrations varied from 0.5 µM to 50 µM when the 
UDPGA concentration was fixed at 2.5 mM; the UDPGA concentrations varied from 1 µM to 
150 µM when the 4-MU concentration was fixed at 50 µM. Kinetic parameters were 
estimated from the fitted curve using a computer program (KaleidaGraph, Synergy Software, 
Reading, PA) designed for non-linear regression analysis. The following equations were 
applied for Michaelis-Menten kinetics: 
V = Vmax • S/ (Km + S) 
where V is the velocity of the reaction, S is the substrate concentration, Km is the 
Michaelis-Menten constant and Vmax is the maximum velocity. Data are expressed as the mean 
± SD of triplicate determinations. 
 
2.6. Treatment of HEK293 cells expressing wild-type UGT1A9 with glycosylation inhibitors 
     The HEK293 cells were transiently transfected with 4 µg of the expression plasmid of 
the wild-type UGT1A9. After 5 h, the cells were treated with tunicamycin (0.025 – 1 µg/ml), 
castanospermine (100 µg/ml), or 1-deoxynojirimycin (40 µM) for 43 h. As a control 
experiment to cause ER stress, the cells were treated with thapsigargin (0.5 µM) for 43 h. The 
total cell homogenates were prepared as described above. 
 
2.7. SDS-PAGE under the non-reducing condition and immunoblotting 
     SDS-PAGE under the non-reducing condition and immunoblotting were performed as 
described previously [17] with slight modifications. The total cell homogenate was 
  8 
solubilized with PBS containing 2% Triton X-100, 0.5% SDS, and 2 mM EDTA, shaking 
vigorously for 60 min at room temperature, and was centrifuged at 13,000 g for 30 min. To a 
24-µl portion of supernatant, 1 µl of 60% glycerol containing 0.2% bromophenol blue was 
added. The sample (23 µg) was applied to Perfect NT Gel M (5-20% gradient, DRC, Tokyo, 
Japan). The electrophoresis was carried out at 10 mA for 5 h at 4?C in Tris-glycine 
electrophoresis buffer (25 mM Tris base, 192 mM glycine, and 0.1% SDS). The separated 
proteins were transferred to a PVDF membrane Immobilon-P, and the membrane was treated 
with rabbit anti-human UGT1A polyclonal antibody as described above. 
 
2.8. Examination of thermal instability of UGT1A9 
     To examine the effects of the deglycosylation on the thermal instability of UGT1A9, the 
reaction mixtures including the cell homogenate but excluding 4-MU were preincubated at 37, 
42, 47, 52 and 57 °C for 15 min in the presence of 2.5 mM UDPGA. The enzyme activities were 
measured by adding 4-MU in a final concentration of 50 µM at 37°C for 20 min. The residual 
activity was determined by comparison with the control activity without the preincubation. 
 
2.9. Statistical analyses 
     Data are expressed as the mean ± SD of three independent determinations. Statistical 
significance of the kinetic parameters was determined by two-tailed Student’s t test. A value 




3.1. SDS-PAGE analysis of Endo H- or O-glycosidase-treated recombinant human UGT1As 
     In the SDS-PAGE analysis, human UGT1A1, UGT1A4, UGT1A6, and UGT1A9 stably 
expressed in HEK293 cells migrated differently (Fig. 1A), although they had quite similar 
numbers of amino acids (527 to 530 residues). To investigate whether the difference was due 
to the glycosylation, UGT1As were treated with Endo H and O-glycosidase, which cleave N- 
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and O-glycosylation sites, respectively. When the UGT1A1, UGT1A4, UGT1A6, and 
UGT1A9 treated with Endo H were separated, they showed the same migration patterns, 
which were faster than those of non-treated UGT1As. In contrast, the treatment with 
O-glycosidase did not affect the migration pattern of the original UGT1As. These results 
suggested that all of UGT1A1, UGT1A4, UGT1A6, and UGT1A9 were N-glycosylated. As 
deduced from the amino acid sequences, UGT1A1 and UGT1A9 have three potential 
N-linked glycosylation sites, NX(S/T) (Fig. 1B). UGT1A4 and UGT1A6 have five and two 
potential N-glycosylation sites, respectively. The differences in the migration of UGT1As on 
SDS-PAGE seemed to be in parallel with the differences in the number of the potential 
N-glycosylation sites. In the subsequent study, we focused on UGT1A9. 
 
3.2. Effects of substitution of asparagine residues at the potential N-glycosylation sites of 
UGT1A9 on the migration on SDS-PAGE and the enzyme activity 
     To investigate the role of the glycosylation on the enzyme activity, three asparagine 
residues at 71, 292, and 344 of UGT1A9, the potential glycosylation sites, were substituted to 
glutamine. On the SDS-PAGE analysis, the single mutants N71Q and N344Q showed two 
bands that migrated faster than those of the wild type (Fig. 2A). The migration of two bands 
of the single mutants N292Q was slightly faster than those of the wild-type UGT1A9. The 
double mutants N71Q/N292Q and N292Q/N344Q showed a single band the migration of 
which was similar to the faster ones observed in the single mutants N71Q and N344Q, 
respectively. The double mutant N71Q/N344Q showed two bands, of which the band with 
faster migration seemed to be the same as the band of the triple mutant N71Q/N299Q/N344Q. 
The migration of the triple mutant was the same as the band of the Endo H-treated wild type. 
These results indicate that all of the three asparagine residues would be glycosylated, although 
the extent of glycosylation and/or size of the glycan at residue 292 would be lower than at the 
other residues. 
     The 4-MU O-glucuronosyltransferase activities by wild-type and mutants UGT1A9 
were determined (Fig. 2B). The activities were normalized with the UGT1A9 protein levels 
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determined by immunoblotting. The kinetics of the activities by the wild-type UGT1A9 was 
fitted to Michaelis-Menten kinetics. With the varied concentrations of 4-MU and the 
concentration of UDPGA fixed at 2.5 mM, the Km and Vmax values were 2.7 ± 0.8 µM and 
2.33 ± 0.29 nmol/min/unit, respectively (Table 2). With the varied concentrations of UDPGA 
and the concentration of 4-MU fixed at 50 µM, the Km and Vmax values were 14.1 ± 1.4 µM 
and 1.23 ± 0.06 nmol/min/unit, respectively. The single mutants N71Q, N292Q, and N344Q 
showed lower Vmax values than that of the wild type, but no difference was observed in the 
Km values in comparison with the wild type. The order of intrinsic clearance was N292Q > 
N344Q > N71Q. The double mutants N71Q/N292Q and N292Q/N344Q showed much lower 
activities, and the double mutant N71Q/N344Q and the triple mutant N71Q/N292Q/N344Q 
showed no activity. These results suggest that the substitution of asparagine residues resulted 
in the production of unglycosylated and inactive protein. 
 
3.3. Effects of treatments with tunicamycin, castanospermine, or 1-deoxynojirimycin on the 
migration on SDS-PAGE and the enzyme activity of UGT1A9 
     In the mutation study, we could not exclude the possibility that the loss of enzyme 
activity may have been due to a change of the protein structure but not due to the lack of 
glycosylation. To investigate the effect of the glycosylation per se on the enzyme activity, we 
produced unglycosylated protein by treatment with tunicamycin, an inhibitor of 
oligosaccharyltransferase, which catalyzes the translocation of oligosaccharide core units 
(Glc)3(Man)9(GlcNAc)2 to polypeptides (Fig. 3A). The treatment of the cells with 
tunicamycin resulted in the production of faster migrating UGT1A9 protein in a 
dose-dependent manner (Fig. 3B). The mobility of the UGT1A9 protein in the cells treated 
with 1 µg/ml tunicamycin was the same as that of the Endo H-treated UGT1A9 protein. Thus, 
we successfully produced unglycosylated UGT1A9 protein. The unglycosylated UGT1A9 
protein showed a dose-dependent reduction in enzyme activity associated with the extent of 
unglycosylation (Fig. 3C). After the glycan core units are transferred to the peptides, the 
terminus glucoses are trimmed by !-glucosidases I and II in the ER and the Golgi apparatus 
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(Fig. 3A). To investigate whether the trimming of the terminus glucose may affect the enzyme 
activity, the cells were treated with castanospermine, an inhibitor of !-glucosidases I and II or 
1-deoxynojirimycin, an inhibitor of !-glucosidases II. On the SDS-PAGE, the mobility of 
UGT1A9 from the cells treated with castanospermine was slightly lower than that of control 
(Fig. 3B). The effects of the treatment with castanospermine and 1-deoxynojirimycin on the 
enzyme activity were insignificant (77% and 80% of the control, respectively) (Fig. 3C). 
These results suggest that the binding of core glycan rather than modification of the terminus 
would be important to exert the enzyme activity.  
     It is known that the treatment of cells with tunicamycin causes ER stress by the 
accumulation of unfolded or misfolded proteins [18,19]. Actually, we observed that the levels 
of glucose-regulated protein 78 (GRP78) and GRP94 were increased in a dose-dependent 
manner by treatment with tunicamycin (Fig. 3B). To verify that the decrease of UGT activity 
would not be due to the secondary effects of ER stress, we determined the UGT activity under 
the treatment with thapsigargin, an inducer of ER stress inhibiting the Ca2+-ATPase on the ER 
membrane [20]. The treatment with thapsigargin caused ER stress, demonstrated by the 
highly increased GRP78 and GRP94, but had little effect on the 4-MU 
O-glucuronosyltransferase activity (81.0% of control) (Fig. 3C). In addition, the treatment 
with castanospermine or 1-deoxynojirimycin also caused ER stress, but their effects on 
UGT1A9 activity were insignificant. These results suggest that the dramatic decrease of 
UGT1A9 activity by tunicamycin treatment would be due to the inhibition of glycosylation 
during the translation. 
 
3.4. Effects of deglycosylation on the enzyme activity of UGT1A9 
     Next, we investigated whether the digestion of glycan from the mature UGT1A9 
protein might affect the enzyme activity. We measured the 4-MU glucuronosyltransferase 
activity of the wild-type UGT1A9 that was treated with Endo H under the non-denaturing 
condition. We first confirmed that UGT1A9 was completely deglycosylated by Endo H (Fig. 
4A). The kinetics of 4-MU glucuronosyltransferase activity by deglycosylated UGT1A9 was 
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similar to that by the non-treated UGT1A9 (Fig. 4B). These results suggest that the glycan per 
se would not be a determinant of the enzyme kinetics. 
 
3.5. Role of N-glycosylation on the protein folding of UGT1A9 
     It was surmised that the decreases of the enzyme activity of mutants UGT1A9 as well 
as the unglycosylated UGT1A9 produced by tunicamycin treatment might result from 
changes in the protein folding of UGT1A9. To investigate whether the inhibition of 
N-glycosylation affects the higher structure of UGT1A9 protein, we performed SDS-PAGE 
under the non-reduced condition analysis. As shown in Fig. 5A, in control, two bands were 
observed at about 53 kDa and 110 kDa, corresponding to a monomer and dimer, respectively, 
as previously reported [17]. The treatment with castanospermine or 1-deoxynojirimycin did 
not affect the higher structure of UGT1A9. Unexpectedly, no band was observed with the 
total cell homogenates from tunicamycin (1 µg/ml)-treated cells, though a clear band was 
observed in the SDS-PAGE analysis. This may imply that the epitope of UGT1A9 toward the 
anti-UGT1As antibody might be sterically distorted. In other words, the folding of UGT1A9 
might be changed by the inhibition of N-glycosylation. To confirm this assumption, we also 
performed the SDS-PAGE under the non-reduced condition analysis for a series of mutant 
UGT1A9 proteins (Fig. 5B). Interestingly, the single mutants N71Q and N344Q showed two 
bands corresponding to a monomer and dimer that were weaker than those of the wild type, 
although the single mutant N292Q did not show a prominent difference in comparison with 
the wild type. Three double mutants barely showed the two monomer and dimer bands. 
Finally, in triple mutants, no clear band was observed, supporting the hypothesis that 
unglycosylated protein would have aberrant protein folding. In contrast, Endo H-treated 
UGT1A9 clearly showed the two bands indicating that the deglycosylation from the correctly 
folded protein did not affect the higher structure of UGT1A9. These results suggest that 
impeding N-glycosylation would cause drastic changes in the folding of UGT1A9. 
 
3.6. Thermally stable characteristics of UGT1A9: asparagine-substituted mutants UGT1A9 
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and Endo H-treated wild-type UGT1A9 
     In our previous study [15], we demonstrated that UGT1A9, among human UGT1A 
isoforms, is uniquely tolerable to heat treatment. The thermal stability of proteins largely 
depends on their three-dimensional structures. To investigate the role of the N-glycosylation 
on the protein folding of UGT1A9, we determined the thermal stability of single mutants of 
UGT1A9 or Endo H-treated wild-type UGT1A9. Double and triple mutants and the 
tunicamycin-treated wild-type UGT1A9 were not used, since their enzyme activities were low. 
The 4-MU O-glucuronosyltransferase activity by the wild-type UGT1A9 was almost 
completely retained by heat treatment up to 52°C (Fig. 5), showing thermal stability 
consistent with our previous study [15]. The activity was decreased by 80% of control by heat 
treatment at 57°C. The single mutants N71Q, N292Q, and N344Q were also stable in 
response to the heat treatment up to 52°C, but treatment at 57°C decreased their activities 
(39%, 52%, and 57% of control, respectively), which were significantly lower than those of 
the wild type. In contrast, the Endo H-treated UGT1A9 showed thermal stability similar to 
that of the non-treated UGT1A9. These results suggest that N-glycosylation would be 
important for the protein folding of UGT1A9.  
 
4. Discussion 
     In the present study, we evaluated the role of N-glycosylation in human UGT1As and 
found that all of the UGT1A1, 1A4, 1A6, and 1A9 were N-glycosylated. It was not a specific 
phenomenon for the recombinant proteins, because we observed the Endo H-dependent shift 
of bands when human liver microsomes were applied for the SDS-PAGE analysis using 
isoform-specific antibodies against human UGT1A1, UGT1A6 (BD Gentest), and UGT1A9 
[21] (data not shown). The numbers of the potential N-glycosylation sites of UGT1A1, 1A4, 
1A6, and 1A9 are 3, 5, 2, and 3, respectively (Fig. 1B), and seem to be in parallel with the 
molecular sizes of these glycoproteins (Fig. 1A). By the mutation analysis, we found that the 
three potential glycosylation sites at position 71, 292, and 344 in UGT1A9 were all 
glycosylated, although the extent of glycosylation and/or size of the glycan at position 292 
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would be low. Previously, Ouzzine et al. [7], using mutation analysis of recombinant enzymes 
expressed in yeast, reported that human UGT1A6 is glycosylated at position 345, but not at 
293. They concluded from the results of the SDS-PAGE and immunoblot analysis that there 
was no difference between the mobility of the mutant N293G and the wild-type UGT1A6. 
Consistent with their finding, as shown in Fig. 2A, the difference in the mobility between the 
mutant N292Q and wild-type UGT1A9 was not large. However, analysis with the 
combination mutants at three sites revealed that N292 would be N-glycosylated. The enzyme 
kinetic analysis also supported this (Fig. 2 and Table 2). Thus, it is conceivable that human 
UGT1As are commonly N-glycosylated at the sites corresponding to N292 and N344 of 
UGT1A9, which are encoded from common exons 2 and 5, although the extent of 
glycosylation and/or size of the glycan are different. The mutation of these asparagine 
residues significantly decreased the Vmax values, but not the Km values (Table 2), consistent 
with a previous study of human UGT2B15 and monkey UGT2B20 [8]. To investigate 
whether the decreased velocity was due to the abolished glycosylation, not by the change in 
primary structure, we further studied the enzyme activity of unglycosylated and 
deglycosylated UGT1A9 proteins. 
The unglycosylated UGT1A9 protein produced by the treatment with tunicamycin was 
enzymatically inactive. In addition, the SDS-PAGE under the non-reduced condition analysis 
revealed that it had aberrant folding. Therefore, the decreased enzyme activity would result 
from the misfolding owing to the abolished glycosylation. The thermal stability assays 
supported the importance of glycosylation in the folding of UGT protein. Once UGTs are 
correctly folded in the presence of glycan, they are enzymatically active, because the 
deglycosylation of UGT1A9 by Endo H did not affect the enzyme activity. These results also 
suggest that the N-glycosylation is important for the folding of UGT proteins. The C-terminal 
half including two N-glycosylation sites is common to UGT1A isoforms. Therefore, it would 
be reasonable to assume that the importance of N-glycosylation is common to UGT1As. 
Supporting it, we found that unglycosylated UGT1A1 protein produced by the treatment with 
tunicamycin was enzymatically inactive, whereas the kinetics of 4-MU 
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glucuronosyltransferase activity by UGT1A6 was also not affected by deglycosylation with 
Endo H (data not shown). However, it should be pointed out that some UGT2B isoforms are 
not glycosylated. Barbier et al. [8] reported that human UGT2B4, monkey UGT2B18 and 
UGT2B23 are not N-glycosylated in spite of the presence of the potential N-glycosylation 
sites. Additionally, there is no potential N-glycosylation site for rat UGT2B3 [9] and 
UGT2B6 [10]. Although the precise mechanisms of the folding of UGTs are not known, 
glycosylated UGTs and non-glycosylated UGTs may be differently regulated. It would be of 
interest to determine whether such a difference affects the higher structures, stabilities, and 
membrane-traffic of UGTs in the future. 
     In the present study, we determined 4-MU glucuronosyltransferase activity to evaluate 
the effects of N-glycosylation on the enzyme activity of UGT1A9. Additionally, to investigate 
whether the effects of N-glycosylation might be different depending on substrates, we also 
determined propofol O-glucuronosyltransferase activities. The unglycosylated UGT1A9 
produced by the treatment with tunicamycin was inactive for propofol O-glucuronidation, and 
the effects of the mutations of each N-glycosylation site on the kinetics of propofol 
glucuronidation were similar with those observed in the 4-MU glucuronidation (data not 
shown). In addition, the kinetics of the deglycosylated UGT1A9 by Endo H was completely 
fitted with that by the non-treated UGT1A9 (data not shown). Thus, it is unlikely that the 
effects of N-glycosylation would be depending on substrates. 
In conclusion, we found that human UGT1A9 was N-glycosylated, and impeding 
N-glycosylation resulted in the loss of function. This study clearly demonstrated that the 
N-glycosylation plays an important role in the protein folding of UGT1A9. 
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Figure legends 
 
Fig. 1. SDS-PAGE and immunoblotting of Endo H- or O-glycosidase-treated human UGT1A 
proteins and potential N-glycosylation site. (A) Total cell homogenates from HEK293 cells 
stably expressing UGT1A1, UGT1A4, UGT1A6, or UGT1A9 were treated with Endo H or 
O-glycosidase as described in Materials and Methods. The samples (10 µg) were subjected to 
10% SDS-PAGE and transferred to a PVDF membrane. The membrane was probed with an 
anti-human UGT1A antibody. (B) Schematic representation of UGT1A proteins and potential 
N-glycosylation sites. UGT1As are generated by alternative splicing of unique exon 1 to 
common exons 2-5, resulting in isoforms with an identical C-terminal half of protein and a 
unique N-terminal half. 
 
Fig. 2. Molecular size and enzyme activity of UGT1A9 mutants. The expression plasmids of 
wild-type and mutants UGT1A9 were transiently transfected into the HEK293 cells. (A) Total 
cell homogenates (10 µg) were separated by 10% SDS-PAGE. Endo H-treated cell 
homogenates (10 µg) expressing wild-type UGT1A9 was also separated to show the 
migration of non-glycosylated UGT1A9. The band density of the wild-type UGT1A9 was 
defined as 1 unit per 10 µg of protein. Values were the mean ± SD of three independent 
determinations. GAPDH levels were examined as a loading control. (B) Kinetic analyses of 
4-MU O-glucuronosyltransferase activities were performed. Total cell homogenates were 
incubated with 0.5 to 50 µM 4-MU and UDPGA fixed at 2.5 mM (left panel), or with 1 - 150 
µM UDPGA and 4-MU fixed at 50 µM (right panel). Data are the mean ± SD of triplicate 
determinations. 
 
Fig. 3. Effects of the inhibitors of glycosylation or glycosidase on UGT1A9. (A) Schematic 
representation of biosynthesis of N-glycosylated protein in ER. Tunicamycin inhibits the first 
step of N-glycosylation, translocation of oligosaccharide core units to peptides. 
Castanospermine inhibits !-glucosidases I and II and 1-deoxynojirimycin inhibits 
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!-glucosidase II (B) HEK293 cells were transiently transfected with the expression plasmid 
of wild-type UGT1A9. After 5 h, the cells were treated with tunicamycin (0.025 to 1 µg/ml), 
an inhibitor of glycosylation, castanospermine (100 µg/ml) or 1-deoxynojirimycin (40 µM), 
inhibitors of glycosidase, for 43 h. To induce ER stress, the cells were treated with 
thapsigargin (0.5 µM) for 24 h. SDS-PAGE and immunoblotting using anti-human UGT1A 
antibody were performed with 10 µg total cell homogenates. Endo H-treated cell homogenate 
expressing wild-type UGT1A9 was applied to show the migration of non-glycosylated 
UGT1A9. The band density of the control UGT1A9 was defined as 1 unit per 10 µg of 
protein. Values were the mean ± SD of three independent determinations. Immunoblotting 
using anti-KDEL antibody was performed with 40 µg total cell homogenates to determine the 
levels of GRP94 and GRP78. The band density of the non-treated cells (control) was defined 
as 1. GAPDH levels were examined as a loading control. (C) 4-MU 
O-glucuronosyltransferase activities were determined with 50 µM 4-MU and 2.5 mM 
UDPGA at 37°C for 20 min. Data are the mean ± SD of triplicate determinations. **P < 0.01 
compared with control. 
 
Fig. 4. Effects of deglycosylation on the enzyme activity of UGT1A9. The total cell 
homogenates (10 µg) prepared from the HEK293 cells transiently expressing UGT1A9 were 
treated with 250 U Endo H under the non-denaturing condition (200 mM Tris-HCl buffer, pH 
7.5) at 37°C for 1 h. (A) SDS-PAGE and immunoblotting were performed. (B) Kinetic 
analyses of 4-MU O-glucuronosyltransferase activities were performed with 1 to 50 µM 
4-MU and UDPGA fixed at 2.5 mM (left panel) or with 2.5 to 150 µM UDPGA and 4-MU 
fixed at 50 µM (right panel). 
 
Fig. 5. SDS-PAGE under the non-reduced condition and immunoblot analysis. Total cell 
homogenates from (A) tunicamycin (1 µg/mL)-, castanospermine (100 µg/ml)- or 
1-deoxynojirimycin (40 µM)-treated HEK293 cells expressing wild-type UGT1A9, and (B) 
the HEK293 cells expressing mutants UGT1A9 were separated on Perfect NT Gel M (5-20% 
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gradient). (C) Endo H-treated homogenates from the HEK293 cells expressing wild-type 
UGT1A9 were also separated. Immunoblotting was performed as described in Materials and 
Methods. 
 
Fig. 6. Thermal instability of wild-type and mutants UGT1A9 (A) as well as Endo H-treated 
UGT1A9 (B). The reaction mixtures including the cell homogenate but excluding 4-MU were 
preincubated at 37, 42, 47, 52 and 57 °C for 15 min in the presence of 2.5 mM UDPGA. The 
enzyme activities were measured by adding 4-MU in a final concentration of 50 µM at 37°C for 
20 min. The residual activity was determined by comparison with the control activity without 
the preincubation. Data are the mean ± SD of triplicate determinations. Control activities were 
as follows: (A) wild-type, 3.09 ± 0.11 nmol/min/unit; N71Q, 0.23 ± 0.01 nmol/min/unit; 
N292Q, 1.69 ± 0.06 nmol/min/unit; N344Q, 0.40 ± 0.02 nmol/min/unit (B) non-treated, 2.53 
± 0.14 nmol/min/unit; Endo H-treated, 2.48 ± 0.06 nmol/min/unit.  
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 Table 1.  Primers used for site-direct mutagenesis of UGT1A9. 
 










 Table 2. Kinetic parameters for 4-MU O-glucuronidation by wild-type and mutants UGT1A9 
expressed in HEK293 cells. 
 
 Wild/Mutants      Km  Vmax   Vmax/Km 
 
Varied concentration of 4-MU   (µM)       (nmol/min/unit)           (µL/min/unit) 
 Wild 2.7 ± 0.8 2.33 ± 0.29  886 ± 142 
 N71Q 2.6 ± 0.1 0.17 ± 0.01** 66 ± 5** 
 N292Q 2.7 ± 0.2 1.09 ± 0.03** 413 ± 33** 
 N344Q 1.9 ± 0.4 0.31 ± 0.01** 164 ± 29** 
 N71Q/N292Q 3.6 ± 0.4 0.05 ± 0.00** 15 ± 1** 
 N71Q/N344Q   ND  ND  ND 
 N292Q/N344Q 2.6 ± 0.4 0.05 ± 0.00** 18 ± 3** 
 N71Q/N292Q/N344Q   ND   ND  ND 
 
Varied concentration of UDPGA   (µM)       (nmol/min/unit)           (µL/min/unit) 
 Wild 14.1 ± 1.4 1.23 ± 0.06  87 ± 5 
 N71Q 16.5 ± 5.6 0.11 ± 0.00**  7 ± 2** 
 N292Q 19.3 ± 3.9 0.97 ± 0.04**  52 ± 11* 
 N344Q 27.3 ± 8.6 0.22 ± 0.04**  8 ± 1** 
 N71Q/N292Q 20.2 ± 11.9 0.02 ± 0.00**  1 ± 1** 
 N71Q/N344Q    ND ND  ND 
 N292Q/N344Q 25.1 ± 2.9** 0.03 ± 0.00**  1 ± 0** 
 N71Q/N292Q/N344Q    ND  ND  ND 
 
 Data are the mean ± SD. **P < 0.01, *P < 0.05 compared with control value.  
